Plain-English translation of NCT04969315 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This is one of the first times this treatment has been tested in people.
This early-stage trial is testing two new medications called and that work by blocking certain immune receptors to help your body fight cancer. You would take one or both of these medications as daily capsules for several months. The study is enrolling people with advanced cancers—including kidney, prostate, lung, head and neck, colon, endometrial, and ovarian cancer—whose cancer has not responded to standard treatments.
Many people with advanced cancer run out of effective treatment options because their cancer stops responding to existing therapies. This medication aims to unlock a different pathway in the immune system, potentially giving patients a new way to fight their cancer when other options have failed.
You likely qualify if…
You likely don't qualify if…
You would visit the study center regularly to receive your assigned medication—either , , or both together—as daily capsules taken at home. Each treatment cycle lasts 28 days, and you would continue for several months while doctors monitor your cancer with scans and blood tests, watching for both side effects and signs that the medication is working. The study is still determining the right dose, so early participants may receive lower doses than later ones as researchers learn what amount is safest and most effective.
AI-generated summary from trial data · Aug 2, 2026 · Not medical advice
United States